

Environmental and Social Data Sheet

Overview

| | |
|--|--|
| Project Name: | <i>ARGENTINA VACCINE PURCHASE</i> |
| Project Number: | <i>20210373</i> |
| Country: | <i>Argentina</i> |
| Project Description: | <i>EIB loan to finance the purchase of COVID-19 vaccines</i> |
| EIA required: | no |
| Project included in Carbon Footprint Exercise ¹ : | no |

Environmental and Social Assessment

The operation supports Argentina's vaccination campaign against COVID-19, as described in the "Strategic Vaccination Plan against COVID 19 in Argentina" (the Plan). In detail, the project will co-finance the purchase of vaccines alongside other IFIs and the Argentine Government to facilitate the deployment of the vaccination campaign as stipulated in the Plan.

Environmental Assessment

Due to the project's characteristics, the project would not fall under Annex I or Annex II of the EIA Directive 2014/52/EU amending Directive 2011/92/EU.

Social Assessment

The proposed project will be dedicated to mitigating the impacts of the novel coronavirus (COVID-19) pandemic on the people and economy of Argentina and will lead to important social benefits stemming from its focus on ensuring fair and equitable access to vaccines successfully developed against the SARS CoV-2 virus. SARS-CoV-2 and the resulting disease COVID 19, are areas of high unmet medical need that have severely congested public health systems and services worldwide and have effectively paralysed the global economy. The need for global equitable access to a SARS-CoV-2 vaccine is significant.

¹ Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO₂e/year absolute (gross) or 20,000 tonnes CO₂e/year relative (net) – both increases and savings.

Luxembourg, 15th September 2021

Conclusions and Recommendations

The project concerns investments in vaccines, which do not fall under Annex I or Annex II of the EIA Directive.

The activities undertaken in the project aim to result in new and improved vaccine access with a positive impact on healthcare. Therefore, if the project is successful, it is expected to have a positive social impact.

Considering the above, the project is acceptable for Bank financing in terms of environmental and social aspects.